ABVC: ABVC BioPharma Inc Company Value to Net Income
The growth in value of ABVC BioPharma is driven by successful trials of plant-based treatments for depression and ADHD, payments from Asian partners, and FDA support. This chart reflects the current market value at -3.80. ABVC BioPharma develops low-toxicity drugs for the therapy of neurological disorders and cancer, utilizing unique patented plant extracts to combat severe pathologies.
%20Price%20to%20Earnings%20Ratio&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_ABVC_-_ABVC-BioPharma_-_Price-to-Earnings-Ratio "abvcpharma.com (ABVC): Market Cap to Earnings from 07/04/2022 to 11/10/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for ABVC BioPharma Inc (ABVC)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio ABVC BioPharma|ABVC - Long-Term Debt to Capital|Current Liabilities to Capital ABVC BioPharma, Inc|ABVC - Company Debts|Debt to Net Assets Ratio ABVC BioPharma, Inc.|ABVC - Company Long-Term Debts|Company Short-Term Debts ABVC BioPharma|Quick Liquidity abvcpharma.com
- business earnings and investment ratios data:
ABVC - Net Income|Expected Profit ABVC BioPharma|ABVC - P/E Multiple|Projected Price to Earnings ABVC BioPharma Inc.|ABVC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation ABVC BioPharma, Inc.|ABVC - Operating profit EBITDA|Earnings per share for the last twelve months ABVC BioPharma|ABVC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months abvcpharma.com|ABVC - Earnings per share growth in current year|Expected net earnings per share growth next year ABVC BioPharma
Comprehensive company analysis:abvcpharma.com - ABVC
The P/E ratio determines the market value of one ruble of net profit, reflecting investor expectations regarding capital payback rates and cost management efficiency. By analyzing the P/E chart for ABVC BioPharma (ABVC), one can assess the company's resilience to geopolitical risks, which directly impact operating profitability and the final market valuation of the business through international supply chain disruptions and patent complexities.
Key competitors
P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|P/E Multiple PCRX (Pacira BioSciences, Inc.)|P/E Multiple ARS Pharmaceuticals Inc SPRY|Theravance - P/E Multiple|AQST: Price to Earnings Ratio|SCPH (scpharmaceuticals.com) - Price to Earnings Ratio|TECX (Tectonic Therapeutic) - Price to Earnings Ratio|TNXP (Tonix Pharmaceuticals Holding Corp.) - P/E Multiple|Price to Earnings Ratio SXT China (SXTC)|Price to Earnings Ratio EPRX (Eupraxia Pharmaceuticals)|BHST (BioHarvest Sciences Inc) - Company Value to Net Income|P/E Multiple EXOZ (eXoZymes Inc)|Oramed - Price to Earnings Ratio|Entera Bio Corp - P/E Multiple|Business Payback Period MindWalk Holdings, Inc. HYFT|Cumberland Pharma (CPIX) - Price to Earnings Ratio|Market Cap to Earnings Quantum BioPharma Corp (QNTM)|Price to Earnings Ratio FibroGen, Inc.|telomirpharma.com - Market Cap to Net Income|P/E Multiple RANI|SNYR (synergychc.com) - Company Value to Net Income|P/E Multiple RLYB (Rallybio)|P/E Multiple Lexaria Bioscience Corp LEXX|PULM - Price to Earnings Ratio|Company Value to Net Income PTHL (Pheton Holdings Ltd)|aptorumgroup.com (APM) - Price to Earnings Ratio|Price to Earnings Ratio Lyra Therapeutics Inc.|IBO (Impact BioMedical) - P/E Multiple|P/E Multiple TNF Pharma|P/E Multiple YCBD|P/E Multiple painreform.com (PRFX)|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals Inc - Price to Earnings Ratio|OPTN: Price to Earnings Ratio|PIRS: Price to Earnings Ratio|PROC: P/E Multiple|Price to Earnings Ratio petrospharma.com|Price to Earnings Ratio Qilian International Holding|Acelyrin Inc. - Market Cap to Net Income|P/E Multiple TFFP
